MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Mesoblast limited Company Profile (NASDAQ:MESO)

Consensus Ratings for Mesoblast limited (NASDAQ:MESO) (?)
Ratings Breakdown: 3 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $8.63 (143.64% upside)

Analysts' Ratings History for Mesoblast limited (NASDAQ:MESO)
Show:
DateFirmActionRatingPrice TargetActions
6/14/2016Credit SuisseDowngradeOutperform -> Neutral$10.00 -> $5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/4/2016Maxim GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/7/2016JPMorgan Chase & Co.DowngradeOverweight -> Neutral$9.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2016Chardan CapitalReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/24/2015Ladenburg ThalmannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/28/2014 forward)
Earnings History for Mesoblast limited (NASDAQ:MESO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
2/16/2016Q216($0.06)$30.00 million$4.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
12/16/2015Q116($0.04)$7.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Mesoblast limited (NASDAQ:MESO)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Mesoblast limited (NASDAQ:MESO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Mesoblast limited (NASDAQ:MESO)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Mesoblast limited (NASDAQ:MESO)
DateHeadline
06/27/16 09:28 AMNext Weeks Broker Price Targets For Mesoblast Limited (NASDAQ:MESO) - Fiscal Standard
06/22/16 09:51 AMCredit Suisse Downgrades Mesoblast limited (ADR) to Neutral with Price Target $5.00 - Trade Calls
06/16/16 09:25 AMMesoblast Ltd (NASDAQ:MESO) Receives 'Neutral' Rating From Brokers At Credit Suisse - FTSE News
06/15/16 05:05 PMWhy have Mesoblast Limited shares soared today? - Motley Fool Australia
06/15/16 05:05 PMThere could be more pain ahead for Mesoblast limited as credibility sinks - Motley Fool Australia
06/15/16 09:46 AMWhy have Mesoblast Limited shares soared today?
06/14/16 04:55 PM5 Stocks That Are Exhibiting Heightened Volatility Today
06/14/16 04:55 PMThere could be more pain ahead for Mesoblast limited as credibility sinks
06/14/16 04:55 PMMesoblast Downgraded To Neutral, Target Price Cut In Half
06/14/16 04:55 PMSynchrony Financial, Wells Fargo and Navistar slip
06/14/16 04:55 PMSynchrony Financial, Wells Fargo and Navistar slip
06/14/16 04:55 PMMesoblast : Teva ends collaboration with Australian co Mesoblast
06/14/16 04:55 PMMesoblast slumps 36% premarket after Teva backs out of MPC-150-IM development
06/14/16 04:55 PMMesoblast Limited (MESO) Regains Worldwide Right to MPC Technology Platform
06/14/16 01:34 PM9 Biggest Mid-Day Losers For Tuesday -   Infinity Pharmaceuticals Inc. (NASDAQ: INFI) shares dipped 70.63 percent to $1.29. Infinity announced plans to cut 21 percent of the workforce. The company also reported that DYNAMO Phase 2 monotherapy study evaluating the efficacy and safety of duvelisib met its primary endpoint. Mesoblast limited (ADR) (NASDAQ: MESO) shares fell 36.03 percent to $4.52 as the company issued an update on global heart failure program. The company reported that it has regained rights to cardiovascular field for cell therapy platform. KemPharm Inc (NASDAQ: KMPH) shares fell 26.23 ...Full story available on Benzinga.com
06/14/16 09:54 AMCRASH! Mesoblast limited shares plunge 42% - Motley Fool Australia
06/14/16 09:54 AMCredit Suisse Downgrades Mesoblast Limited (MESO) to Neutral - StreetInsider.com
06/14/16 09:54 AMMesoblast Limited (MESO) Regains Worldwide Right to MPC Technology Platform - StreetInsider.com
06/14/16 05:16 AMMesoblast downgraded by Credit Suisse -
06/14/16 05:00 AM6:00 am Mesoblast provides update on global heart failure program; regains rights to cardiovascular field for cell therapy platform; FDA approved second navigational catheter system (halted since June 1) -
06/10/16 05:22 PMMesoblast Limited: Extension of Voluntary Suspension - The Wall Street Transcript
06/10/16 08:05 AMExtension of Voluntary Suspension - irasia.com (press release)
06/10/16 08:05 AMMesoblast limited could be about to sink or soar - Motley Fool Australia
06/07/16 05:19 PMAdult Stem Cells Global Market Professional Survey Report 2016
06/06/16 08:50 AMMesoblast limited's (MESO) Buy Rating Reiterated at Maxim Group - Let Me Know About This
06/03/16 07:55 AMMesoblast limited trading halt leaves investors guessing - Motley Fool Australia - Mesoblast limited trading halt leaves investors guessingMotley Fool AustraliaRegenerative medicine business Mesoblast limited (ASX: MSB) has requested more time before it makes an announcement to the market regarding 'material corporate developments with respect to certain assets of the company'. The shares were ...
06/01/16 07:58 AMMesoblast limited trading halt leaves it on the edge - Motley Fool Australia - Mesoblast limited trading halt leaves it on the edgeMotley Fool AustraliaShares in regenerative medicine business Mesoblast limited (ASX: MSB) are locked in a trading halt this afternoon with the company set to announce “material corporate developments with respect to certain assets of the company”. Although the company is ...and more »
05/30/16 08:07 PMAfter Last Week What Do Analysts Think Of Mesoblast Limited (NASDAQ:MESO) - Share Trading News - After Last Week What Do Analysts Think Of Mesoblast Limited (NASDAQ:MESO)Share Trading News03/07/2016 – Mesoblast Limited was downgraded to “neutral” by analysts at JP Morgan. They now have a USD 10 price target on the stock. 02/19/2016 – Chardan Capital began new coverage on Mesoblast Limited giving the company a “neutral” rating.and more »
05/25/16 09:44 AMMesoblast limited Declines A lot Today, Is Now One of The Worst Performer - Wall Street Hints and News - Mesoblast limited Declines A lot Today, Is Now One of The Worst PerformerWall Street Hints and NewsThe stock of Mesoblast limited (ASX:MSB) is a huge mover today! The stock is down 2.97% or $0.06 after the news, hitting $1.96 per share. About 518,773 shares traded hands. Mesoblast limited (ASX:MSB) has declined 40.06% since October 27, 2015 and is ...and more »
05/23/16 09:50 AMMesoblast Limited (NASDAQ:MESO) Broker Price Targets For The Coming Week - Share Trading News - Mesoblast Limited (NASDAQ:MESO) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Mesoblast Limited (NASDAQ:MESO). The latest reports which are currently in issue on Sunday 22nd of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, ...and more »
05/21/16 09:53 AMLatest Analyst Ratings For Mesoblast Limited (NASDAQ:MESO) - Share Trading News - Latest Analyst Ratings For Mesoblast Limited (NASDAQ:MESO)Share Trading News03/07/2016 – Mesoblast Limited was downgraded to “neutral” by analysts at JP Morgan. They now have a USD 10 price target on the stock. 02/19/2016 – Chardan Capital began new coverage on Mesoblast Limited giving the company a “neutral” rating.
05/21/16 09:53 AMRevenue Update on Mesoblast limited (ADR)(NASDAQ:MESO) - Trade Calls - Revenue Update on Mesoblast limited (ADR)(NASDAQ:MESO)Trade CallsMesoblast limited (ADR)(NASDAQ:MESO) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during After-hours on May 9, 2016. Company reported revenue of $4.14M. Analysts estimated a revenue of $36.73M. Earnings per ...
05/20/16 09:48 AMMesoblast receives $6.2M for R&D - Mesoblast Limited (ASX:MSB) has announced it has received $6.2 million from the Australian Government. The funding is for activities conducted in the 2015 financial year, and was provided under the Government’s R&D Tax Incentive Program. Mesoblast ...
05/20/16 09:48 AMMesoblast : Receives $6.2m From Aus Govt For R&D - Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that it has received $6.2 million from the Australian Government for Research & Development (R&D) activities conducted during the 2015 financial year. The funds were provided to Mesoblast under the ...
05/19/16 07:32 PMMesoblast Receives $6.2m From Aus Govt For R&D - [at noodls] - MESOBLAST ACQUIRES HARVARD TECHNOLOGY TO PRODUCE NEXT GENERATION CELL-BASED MEDICINES MESOBLAST RECEIVES $6.2 MILLION FROM AUSTRALIAN GOVERNMENT FOR RESEARCH AND DEVELOPMENT ACTIVITIES New York, USA; and ...
05/13/16 09:25 AMThe promise of adult stem cells, how the Catholic Church supports it - Washington Times - Washington TimesThe promise of adult stem cells, how the Catholic Church supports itWashington TimesAmong those at the conference was Dr. Donna Skerrett, M.D., the chief medical officer of the Australia-based medical company Mesoblast Limited. She said her company's stem cell research appears to have aided treatments for complications in organ ...and more »
05/12/16 06:47 PMCeasing to be a substantial holder-JP Morgan - [at noodls] - 2c8f0693-93ac-4e19-850c-2215f671b663.pdf Form 605 Corporations Act 2001 Section 6718 Notice of ceasing to be a substantial holder To Company Name/Scheme Mesobl ast Limited ACN/ARSN 1 09 431 870 Details ...
05/12/16 09:22 AMMesoblast Reports Financial Results for Period Ended 31 March 2016 and Provides Corporate Update - irasia.com (press release) - Mesoblast Reports Financial Results for Period Ended 31 March 2016 and Provides Corporate Updateirasia.com (press release)Melbourne, Australia (10 May 2016); and New York, USA (9 May 2016): Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today reported its consolidated financial results and operational highlights for the third quarter and nine months ended 31 March 2016.
05/11/16 09:28 AMThis is why these 4 ASX shares got smashed today - Motley Fool Australia - This is why these 4 ASX shares got smashed todayMotley Fool AustraliaMesoblast limited (ASX: MSB) shares have dropped around 3% today to $1.95 after the company failed to respond satisfactorily to analyst questioning on Tuesday's third quarter earnings call. According to the Sydney Morning Herald, its answers have cast ...and more »
05/09/16 11:10 PMMesoblast cuts third-quarter net loss - [Other] - Stem cell therapy company Mesoblast has narrowed its third-quarter loss thanks to falls in research and development expenses and in administration costs. The dual-listed Mesoblast - which made a disappointing ...
05/09/16 06:38 PMMesoblast Provides Q3 Financial Results and Corporate Update - [Other] - 312401cf-eab9-46aa-9914-0cfe1796404d.pdf MESOBLAST REPORTS FINANCIAL RESULTS FOR PERIOD ENDED 31 MARCH 2016 AND PROVIDES CORPORATE UPDATE Melbourne, Australia (10 May 2016); and New York, USA (9 May 2016): ...
05/09/16 06:18 PMThird Quarter Financial Results On Form 6-K - [at noodls] - a3b68ad3-5bd6-4b56-b0d7-fbb233706ce6.pdf UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities ...
05/09/16 06:18 PMThird Quarter Results Presentation - [at noodls] - bf35b119-c8e5-4870-8c32-773373d9a1e2.pdf Financial Results for the Nine Months And Third Quarter Ended 31 March 2016 May 2016 CAUTIONARY NOTE REGARDING FORWARD-­‐LOOKING STATEMENTS This presenta,on includes ...
05/09/16 06:04 PMMesoblast Reports Financial Results for Period Ended 31 March 2016 and Provides Corporate Update - [GlobeNewswire] - MELBOURNE, Australia and NEW YORK, May 09, 2016-- Mesoblast Limited today reported its consolidated financial results and operational highlights for the third quarter and nine months ended 31 March 2016.. ...
05/09/16 09:31 AMAnalysts Set Mesoblast limited (NASDAQ:MESO) Price Target at $12.25 - Washington News Wire - Analysts Set Mesoblast limited (NASDAQ:MESO) Price Target at $12.25Washington News WireMesoblast limited logo Shares of Mesoblast limited (NASDAQ:MESO) have earned a consensus recommendation of “Buy” from the six research firms that are presently covering the firm, AnalystRatings.Net reports. Two analysts have rated the stock with a hold ...Mesoblast Limited (NASDAQ:MESO) Broker Price Targets For The Coming WeekShare Trading Newsall 3 news articles »
05/09/16 04:16 AMChange in substantial holding-J.P.Morgan - [at noodls] - 2d2e67b2-bc4b-4316-b450-f7d78ca86c64.pdf Form 604 Corporations Law Section 6718 Notice of change of interests of substantial holder To Company Name/Scheme Mesoblast Limited ACN/ARSN 109 431 870 Details ...
05/08/16 08:56 AMHow Analysts Feel About Mesoblast limited (ADR) After Today's Gap Down? - B.O.D.Y Confidential - Web Breaking NewsHow Analysts Feel About Mesoblast limited (ADR) After Today's Gap Down?B.O.D.Y ConfidentialThe stock of Mesoblast limited (ADR) (NASDAQ:MESO) gapped down by $0.05 today and has $6.98 target or 7.00% below today's $7.50 share price. The 5 months technical chart setup indicates high risk for the $560.25M company. The gap down was ...Mesoblast limited (MESO) Scheduled to Post Quarterly Earnings on MondayWeb Breaking Newsall 2 news articles »
05/06/16 09:36 AMMesoblast to Host Third Quarter and Nine Months Financial Results Conference Call and Webcast - EIN News (press release) - Mesoblast to Host Third Quarter and Nine Months Financial Results Conference Call and WebcastEIN News (press release)NEW YORK and MELBOURNE, Australia, May 06, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced it will report financial results for the third quarter/nine months ended March 31 2016 and provide a corporate ...
05/06/16 07:53 AMMesoblast to Host Third Quarter and Nine Months Financial Results Conference Call and Webcast - [GlobeNewswire] - NEW YORK and MELBOURNE, Australia, May 06, 2016-- Mesoblast Limited today announced it will report financial results for the third quarter/nine months ended March 31 2016 and provide a corporate update ...
05/05/16 09:09 AMAre we close to the stem cell revolution? - Lab News - Lab NewsAre we close to the stem cell revolution?Lab NewsA great deal of progress and hard work in this area has already been achieved by companies like Athersys and Mesoblast, which have identified the potential utility of MSCs. One technology belonging to Cynata Therapeutics Ltd and known as Cymerus ...and more »
About Mesoblast limited

Mesoblast limited logoMesoblast Limited is engaged in the development of adult stem cell technology platform for commercialization. The Company develops a portfolio of regenerative therapeutic cell-based products. Its portfolio of therapeutic products is being developed using its technology platforms, which include specialized cells known as mesenchymal lineage adult stem cells (MLCs), to treat conditions with unmet medical needs, including cardiac diseases, spine and musculoskeletal disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. Its products have been prioritized into two tiers: tier 1 product candidates, which represents its lead programs where it focuses on time and resources, such as MPC-06-ID, MPC-150-IM, JR-031, MPC-300-IV and MSC-100-IV, and tier 2 product candidates, which advances to tier 1 depending on newly-generated data, market opportunity or partnering options, such as MSC-100-IV, MPC-25-IC, MPC-25-Osteo and MPC-CBE.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: MESO
  • CUSIP:
Key Metrics:
  • Previous Close: $3.54
  • 50 Day Moving Average: $6.25
  • 200 Day Moving Average: $6.98
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $267.00M
  • Current Quarter EPS Consensus Estimate: $-0.70 EPS
Additional Links:
Mesoblast limited (NASDAQ:MESO) Chart for Tuesday, June, 28, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha